Investors: Press Releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib

Regulatory

Allarity Therapeutics Completes Oversubscribed Rights Issue

Regulatory

Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – March 2021

Regulatory

Allarity Therapeutics Publishes Prospectus Supplement

Non-Regulatory

Allarity Therapeutics Invites Investors for Q1 2021 Report Conference Call

Regulatory

Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics

Regulatory

Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue

Regulatory

Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue

Regulatory

Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress

Regulatory

MINUTES OF ANNUAL GENERAL MEETING 2021

Regulatory

Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib

Regulatory

Notice of Annual General Meeting

Regulatory

Allarity Therapeutics Publishes its Annual Report for 2020

Non-Regulatory

Allarity Therapeutics Invites Investors for FY/Q4 2020 Report Conference Call

Regulatory

Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million

Regulatory

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

Regulatory

Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer

Regulatory

Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus

Regulatory

Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Sign up for press releases

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S.